Vivos Therapeutics (NASDAQ: VVOS) Q2 Earnings: Navigating Growth and Liquidity in Sleep Apnea Market

• Vivos Therapeutics surpassed analyst expectations for Q2 2026 earnings per share (EPS), reporting -$0.31 against an estimated -$0.42.
• Despite the EPS beat, Vivos Therapeutics' revenue for the quarter reached $5.15 million, falling short of the analyst consensus of $5.63 million.
• The company's financial health shows potential liquidity challenges, highlighted by a current ratio of 0.21 and a negative debt-to-equity ratio of -3.18.

Vivos Therapeutics (NASDAQ: VVOS) is a medical device and healthcare services company that focuses on innovative treatments for obstructive sleep apnea (OSA). As highlighted by GlobeNewswire, the company sees steadily increasing patient demand for its OSA solutions. The company's management believes it is laying the foundation for significant future revenue growth in the sleep apnea market.

On August 14, 2026, Vivos Therapeutics reported its second-quarter financial results. The company announced an earnings per share (EPS) of -$0.31. This result surpassed the analyst consensus estimate of -$0.42. EPS is a key measure of a company's profitability that is allocated to each share of its stock.

While earnings beat expectations, Vivos Therapeutics' revenue fell short. Vivos Therapeutics reported revenues of $5.15 million for the period, which was below the analyst estimate of $5.63 million. Despite the revenue miss, the company's CEO described the quarter as a "watershed moment" for future growth, as highlighted by GlobeNewswire, emphasizing the long-term investment outlook.

The company's financial metrics indicate it is not currently profitable. It has a trailing price-to-earnings (P/E) ratio of -0.17. A negative P/E ratio occurs when a company has negative earnings, or a net loss, over the past year. This is also reflected in its negative earnings yield of -4.22, providing crucial insights for investors.

The company's balance sheet shows potential liquidity challenges. Its current ratio of 0.21 indicates that its current liabilities are greater than its current assets, which can signal short-term financial pressure. Furthermore, a debt-to-equity ratio of -3.18 suggests Vivos Therapeutics has negative shareholder equity, where total liabilities exceed total assets, impacting its overall financial health and stock analysis.